MediPines today announced that the Centers for Medicare & Medicaid Services (CMS) finalized an increase in the 2027 Medicare hospital outpatient facility payment, with a national average rate of $150 for noninvasive cardiorespiratory assessment using MediPines AGM100 pulmonary gas exchange technology.

The Current Procedural Terminology (CPT) code 0893T, used for AGM100 assessment, describes noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status. The service is assigned to Ambulatory Payment Classification APC 5734 for hospital outpatient services. The $150 rate applies only to the hospital outpatient facility payment. Any payment for professional services is determined separately.

The MediPines AGM100 is an FDA-cleared, advanced pulmonary gas exchange technology that provides Oxygen Deficit, a noninvasive measure of respiratory impairment severity and a surrogate for the alveolar–arterial oxygen difference (AaDO₂). In one brief session, AGM100 gives clinicians a clearer picture of respiratory impairment by assessing gas exchange, the primary function of the lungs.

The technology uses a noninvasive breathing test to assess patients with chronic or acute respiratory conditions at the site of care. Used in emergency departments, hospital units, and outpatient clinics, it helps clinicians assess the severity of respiratory impairment by evaluating ventilation, blood oxygenation, and gas exchange —how effectively the lungs transfer oxygen into circulating blood. This information helps clinicians make diagnostic and treatment decisions, evaluate treatment response, and determine whether escalation of care is needed.

News of the Medicare payment update follows last year’s NIH-funded study published in the Journal of Clinical Medicine. Conducted in the emergency departments of two academic medical centers, the study evaluated Oxygen Deficit as an early indicator of respiratory deterioration requiring clinical intervention. The researchers used the need for supplemental oxygen within 24 hours as a marker of respiratory deterioration. Oxygen Deficit predicted that need with an AUROC of 0.94 and remained a significant predictor in multivariable analysis (p < 0.001).

The study’s authors, McGuire et al., noted that the AGM100 provides prognostic information “with a fidelity that exceeds or matches the accuracy of the best predictive tools for respiratory failure in the published literature.”

“These findings are significant for hospital outpatient and emergency care,” said Steve Lee, CEO of MediPines. “Patients with a COPD exacerbation, heart failure, or pulmonary embolism can come in with similar symptoms, but the degree of gas exchange impairment can vary, impacting clinical decisions. That’s why assessing gas exchange at the point of care matters.”

Orange County, California-based MediPines is a pioneer and market leader in non-invasive pulmonary gas exchange technology. AGM100 is used by medical providers and clinicians to raise diagnostic accuracy, improve treatment decisions, and accelerate healthcare decision-making. The company manufactures the AGM100 in an FDA-registered MDSAP/ISO13485 certified medical manufacturing facility in California. Learn more at medipines.com.

CPT is a registered trademark of the American Medical Association (AMA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110059132/en/

AGM100 provides prognostic information “with a fidelity that exceeds or matches the accuracy of the best predictive tools for respiratory failure in the published literature.”